{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T04:02:54Z","timestamp":1775102574999,"version":"3.50.1"},"reference-count":66,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,9,19]],"date-time":"2018-09-19T00:00:00Z","timestamp":1537315200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Med"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1186\/s12916-018-1145-0","type":"journal-article","created":{"date-parts":[[2018,8,24]],"date-time":"2018-08-24T14:23:59Z","timestamp":1535120639000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Practical issues in clinical scenarios involving CKD patients requiring antithrombotic therapy in light of the 2017 ESC guideline recommendations"],"prefix":"10.1186","volume":"16","author":[{"given":"Adrian","family":"Covic","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Simonetta","family":"Genovesi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patrick","family":"Rossignol","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philip A.","family":"Kalra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alberto","family":"Ortiz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maciej","family":"Banach","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3424-1588","authenticated-orcid":false,"given":"Alexandru","family":"Burlacu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,9,19]]},"reference":[{"key":"1145_CR1","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1093\/eurheartj\/ehx419","volume":"39","author":"M Valgimigli","year":"2018","unstructured":"Valgimigli M, Bueno H, Byrne RA, Collet JP, Costa F, Jeppsson A, et al. 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS: the task force for dual antiplatelet therapy in coronary artery disease of the European Society of Cardiology (ESC) and of the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J. 2018;39:213\u201360.","journal-title":"Eur Heart J"},{"key":"1145_CR2","doi-asserted-by":"publisher","first-page":"68","DOI":"10.4244\/EIJV11I1A11","volume":"11","author":"M Valgimigli","year":"2015","unstructured":"Valgimigli M, Costa F, Byrne R, Haude M, Baumbach A, Windecker S. Dual antiplatelet therapy duration after coronary stenting in clinical practice: results of an EAPCI survey. EuroIntervention. 2015;11:68\u201374.","journal-title":"EuroIntervention"},{"key":"1145_CR3","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1111\/j.1365-2796.2009.02204.x","volume":"268","author":"K Szummer","year":"2010","unstructured":"Szummer K, Lundman P, Jacobson SH, Schon S, Lindback J, Stenestrand U, et al. Relation between renal function, presentation, use of therapies and in-hospital complications in acute coronary syndrome: data from the SWEDEHEART register. J Intern Med. 2010;268:40\u20139.","journal-title":"J Intern Med"},{"issue":"12","key":"1145_CR4","doi-asserted-by":"publisher","first-page":"1967","DOI":"10.1093\/ndt\/gfx041","volume":"32","author":"A Burlacu","year":"2017","unstructured":"Burlacu A, Genovesi S, Ortiz A, Kanbay M, Rossignol P, Banach M, et al. The quest for equilibrium: exploring the thin red line between bleeding and ischaemic risks in the management of acute coronary syndromes in chronic kidney disease patients. Nephrol Dial Transplant. 2017;32(12):1967\u201376.","journal-title":"Nephrol Dial Transplant"},{"key":"1145_CR5","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1016\/j.phrs.2017.12.004","volume":"129","author":"A Burlacu","year":"2018","unstructured":"Burlacu A, Genovesi S, Goldsmith D, Rossignol P, Ortiz A, Kalra PA, et al. Bleeding in advanced CKD patients on antithrombotic medication - a critical appraisal. Pharmacol Res. 2018;129:535\u201343.","journal-title":"Pharmacol Res"},{"key":"1145_CR6","doi-asserted-by":"publisher","first-page":"1735","DOI":"10.1001\/jama.2016.3775","volume":"315","author":"RW Yeh","year":"2016","unstructured":"Yeh RW, Secemsky EA, Kereiakes DJ, Normand SL, Gershlick AH, Cohen DJ, et al. Development and validation of a prediction rule for benefit and harm of dual antiplatelet therapy beyond 1 year after percutaneous coronary intervention. JAMA. 2016;315:1735\u201349.","journal-title":"JAMA"},{"key":"1145_CR7","doi-asserted-by":"publisher","first-page":"2224","DOI":"10.1016\/j.jacc.2016.02.064","volume":"67","author":"U Baber","year":"2016","unstructured":"Baber U, Mehran R, Giustino G, Cohen DJ, Henry TD, Sartori S, et al. Coronary thrombosis and major bleeding after PCI with drug-eluting stents: risk scores from PARIS. J Am Coll Cardiol. 2016;67:2224\u201334.","journal-title":"J Am Coll Cardiol"},{"key":"1145_CR8","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.1016\/S0140-6736(17)30397-5","volume":"389","author":"F Costa","year":"2017","unstructured":"Costa F, van Klaveren D, James S, Heg D, Raber L, Feres F, et al. Derivation and validation of the predicting bleeding complications in patients undergoing stent implantation and subsequent dual antiplatelet therapy (PRECISE-DAPT) score: a pooled analysis of individual-patient datasets from clinical trials. Lancet. 2017;389:1025\u201334.","journal-title":"Lancet"},{"key":"1145_CR9","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1016\/S0140-6736(13)61170-8","volume":"382","author":"GW Stone","year":"2013","unstructured":"Stone GW, Witzenbichler B, Weisz G, Rinaldi MJ, Neumann FJ, Metzger DC, et al. Platelet reactivity and clinical outcomes after coronary artery implantation of drug-eluting stents (ADAPT-DES): a prospective multicentre registry study. Lancet. 2013;382:614\u201323.","journal-title":"Lancet"},{"key":"1145_CR10","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1111\/jth.13211","volume":"14","author":"A Polzin","year":"2016","unstructured":"Polzin A, Dannenberg L, Sansone R, Levkau B, Kelm M, Hohlfeld T, et al. Antiplatelet effects of aspirin in chronic kidney disease patients. J Thromb Haemost. 2016;14:375\u201380.","journal-title":"J Thromb Haemost"},{"key":"1145_CR11","doi-asserted-by":"publisher","first-page":"1292","DOI":"10.1016\/j.amjcard.2009.06.049","volume":"104","author":"SH Park","year":"2009","unstructured":"Park SH, Kim W, Park CS, Kang WY, Hwang SH, Kim W. A comparison of clopidogrel responsiveness in patients with versus without chronic renal failure. Am J Cardiol. 2009;104:1292\u20135.","journal-title":"Am J Cardiol"},{"key":"1145_CR12","doi-asserted-by":"publisher","first-page":"916","DOI":"10.1053\/j.ajkd.2014.11.023","volume":"65","author":"KH Jeong","year":"2015","unstructured":"Jeong KH, Cho JH, Woo JS, Kim JB, Kim WS, Lee TW, et al. Platelet reactivity after receiving clopidogrel compared with ticagrelor in patients with kidney failure treated with hemodialysis: a randomized crossover study. Am J Kidney Dis. 2015;65:916\u201324.","journal-title":"Am J Kidney Dis"},{"key":"1145_CR13","doi-asserted-by":"publisher","first-page":"1708","DOI":"10.1093\/eurheartj\/eht042","volume":"34","author":"S Agewall","year":"2013","unstructured":"Agewall S, Cattaneo M, Collet JP, Andreotti F, Lip GY, Verheugt FW, et al. Expert position paper on the use of proton pump inhibitors in patients with cardiovascular disease and antithrombotic therapy. Eur Heart J. 2013;34:1708\u201313. 1713a\u20131713b","journal-title":"Eur Heart J"},{"key":"1145_CR14","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1161\/CIRCULATIONAHA.111.019745","volume":"125","author":"GV Moukarbel","year":"2012","unstructured":"Moukarbel GV, Bhatt DL. Antiplatelet therapy and proton pump inhibition: clinician update. Circulation. 2012;125:375\u201380.","journal-title":"Circulation"},{"key":"1145_CR15","doi-asserted-by":"publisher","first-page":"1909","DOI":"10.1056\/NEJMoa1007964","volume":"363","author":"DL Bhatt","year":"2010","unstructured":"Bhatt DL, Cryer BL, Contant CF, Cohen M, Lanas A, Schnitzer TJ, et al. Clopidogrel with or without omeprazole in coronary artery disease. N Engl J Med. 2010;363:1909\u201317.","journal-title":"N Engl J Med"},{"issue":"10093","key":"1145_CR16","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1016\/S0140-6736(17)30770-5","volume":"390","author":"L Li","year":"2017","unstructured":"Li L, Geraghty OC, Mehta Z, Rothwell PM. Age-specific risks, severity, time course, and outcome of bleeding on long-term antiplatelet treatment after vascular events: a population-based cohort study. Lancet. 2017;390(10093):490\u20139.","journal-title":"Lancet"},{"key":"1145_CR17","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1001\/jamainternmed.2015.7193","volume":"176","author":"B Lazarus","year":"2016","unstructured":"Lazarus B, Chen Y, Wilson FP, Sang Y, Chang AR, Coresh J, et al. Proton pump inhibitor use and the risk of chronic kidney disease. JAMA Intern Med. 2016;176:238\u201346.","journal-title":"JAMA Intern Med"},{"key":"1145_CR18","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1186\/s12882-016-0325-4","volume":"17","author":"P Arora","year":"2016","unstructured":"Arora P, Gupta A, Golzy M, Patel N, Carter RL, Jalal K, et al. Proton pump inhibitors are associated with increased risk of development of chronic kidney disease. BMC Nephrol. 2016;17:112.","journal-title":"BMC Nephrol"},{"key":"1145_CR19","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1007\/s40620-016-0309-2","volume":"29","author":"DG Moledina","year":"2016","unstructured":"Moledina DG, Perazella MA. PPIs and kidney disease: from AIN to CKD. J Nephrol. 2016;29:611\u20136.","journal-title":"J Nephrol"},{"key":"1145_CR20","doi-asserted-by":"publisher","first-page":"65","DOI":"10.5414\/CNP68065","volume":"68","author":"UC Brewster","year":"2007","unstructured":"Brewster UC, Perazella MA. Proton pump inhibitors and the kidney: critical review. Clin Nephrol. 2007;68:65\u201372.","journal-title":"Clin Nephrol"},{"key":"1145_CR21","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1038\/ki.2014.74","volume":"86","author":"ML Blank","year":"2014","unstructured":"Blank ML, Parkin L, Paul C, Herbison P. A nationwide nested case-control study indicates an increased risk of acute interstitial nephritis with proton pump inhibitor use. Kidney Int. 2014;86:837\u201344.","journal-title":"Kidney Int"},{"key":"1145_CR22","doi-asserted-by":"publisher","first-page":"1482","DOI":"10.1016\/j.kint.2016.12.021","volume":"91","author":"Y Xie","year":"2017","unstructured":"Xie Y, Bowe B, Li T, Xian H, Yan Y, Al-Aly Z. Long-term kidney outcomes among users of proton pump inhibitors without intervening acute kidney injury. Kidney Int. 2017;91:1482\u201394.","journal-title":"Kidney Int"},{"key":"1145_CR23","doi-asserted-by":"publisher","first-page":"3153","DOI":"10.1681\/ASN.2015121377","volume":"27","author":"Y Xie","year":"2016","unstructured":"Xie Y, Bowe B, Li T, Xian H, Balasubramanian S, Al-Aly Z. Proton pump inhibitors and risk of incident CKD and progression to ESRD. J Am Soc Nephrol. 2016;27:3153\u201363.","journal-title":"J Am Soc Nephrol"},{"key":"1145_CR24","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1053\/j.ajkd.2011.10.045","volume":"59","author":"D Alexopoulos","year":"2012","unstructured":"Alexopoulos D, Xanthopoulou I, Panagiotou A, Komninakis D, Germanos N, Goudas P, et al. Prevalence of inadequate platelet inhibition by clopidogrel in patients receiving hemodialysis. Am J Kidney Dis. 2012;59:469\u201371.","journal-title":"Am J Kidney Dis"},{"key":"1145_CR25","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1016\/j.jacc.2010.04.047","volume":"56","author":"L Bonello","year":"2010","unstructured":"Bonello L, Tantry US, Marcucci R, Blindt R, Angiolillo DJ, Becker R, et al. Consensus and future directions on the definition of high on-treatment platelet reactivity to adenosine diphosphate. J Am Coll Cardiol. 2010;56:919\u201333.","journal-title":"J Am Coll Cardiol"},{"issue":"4","key":"1145_CR26","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1016\/j.kint.2017.11.019","volume":"93","author":"P Roy-Chaudhury","year":"2018","unstructured":"Roy-Chaudhury P, Tumlin JA, Koplan BA, Costea AI, Kher V, Williamson D, et al. Primary outcomes of the monitoring in Dialysis study indicate that clinically significant arrhythmias are common in hemodialysis patients and related to dialytic cycle. Kidney Int. 2018;93(4):941\u201351.","journal-title":"Kidney Int"},{"key":"1145_CR27","doi-asserted-by":"publisher","first-page":"1324","DOI":"10.2215\/CJN.04470908","volume":"4","author":"G Coritsidis","year":"2009","unstructured":"Coritsidis G, Sutariya D, Stern A, Gupta G, Carvounis C, Arora R, et al. Does timing of dialysis in patients with ESRD and acute myocardial infarcts affect morbidity or mortality? Clin J Am Soc Nephrol. 2009;4:1324\u201330.","journal-title":"Clin J Am Soc Nephrol"},{"key":"1145_CR28","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1053\/j.ajkd.2007.06.017","volume":"50","author":"MJ Elliott","year":"2007","unstructured":"Elliott MJ, Zimmerman D, Holden RM. Warfarin anticoagulation in hemodialysis patients: a systematic review of bleeding rates. Am J Kidney Dis. 2007;50:433\u201340.","journal-title":"Am J Kidney Dis"},{"key":"1145_CR29","doi-asserted-by":"publisher","first-page":"1967","DOI":"10.1016\/S0140-6736(09)61751-7","volume":"374","author":"R Sorensen","year":"2009","unstructured":"Sorensen R, Hansen ML, Abildstrom SZ, Hvelplund A, Andersson C, Jorgensen C, et al. Risk of bleeding in patients with acute myocardial infarction treated with different combinations of aspirin, clopidogrel, and vitamin K antagonists in Denmark: a retrospective analysis of nationwide registry data. Lancet. 2009;374:1967\u201374.","journal-title":"Lancet"},{"key":"1145_CR30","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1016\/j.jacc.2013.05.029","volume":"62","author":"M Lamberts","year":"2013","unstructured":"Lamberts M, Gislason GH, Olesen JB, Kristensen SL, Schjerning Olsen AM, Mikkelsen A, et al. Oral anticoagulation and antiplatelets in atrial fibrillation patients after myocardial infarction and coronary intervention. J Am Coll Cardiol. 2013;62:981\u20139.","journal-title":"J Am Coll Cardiol"},{"key":"1145_CR31","doi-asserted-by":"publisher","first-page":"1735","DOI":"10.2215\/CJN.02170216","volume":"11","author":"J Ishigami","year":"2016","unstructured":"Ishigami J, Grams ME, Naik RP, Coresh J, Matsushita K. Chronic kidney disease and risk for gastrointestinal bleeding in the community: the atherosclerosis risk in communities (ARIC) study. Clin J Am Soc Nephrol. 2016;11:1735\u201343.","journal-title":"Clin J Am Soc Nephrol"},{"issue":"6","key":"1145_CR32","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1111\/pace.13331","volume":"41","author":"C Ronpichai","year":"2018","unstructured":"Ronpichai C, Charat T, Tanyanan T, Wisit K, Pavida P, Wisit C. Safety and efficacy of apixaban versus warfarin in patients with end-stage renal disease: meta-analysis. Pacing Clin Electrophysiol. 2018;41(6):627\u201334.","journal-title":"Pacing Clin Electrophysiol"},{"issue":"24","key":"1145_CR33","doi-asserted-by":"publisher","first-page":"2314","DOI":"10.1093\/eurheartj\/ehy060","volume":"39","author":"MP Turakhia","year":"2018","unstructured":"Turakhia MP, Blankestijn PJ, Carrero JJ, Clase CM, Deo R, Herzog CA, et al. Chronic kidney disease and arrhythmias: conclusions from a kidney disease: improving global outcomes (KDIGO) controversies conference. Eur Heart J. 2018;39(24):2314\u201325.","journal-title":"Eur Heart J"},{"key":"1145_CR34","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1016\/S0140-6736(12)62177-1","volume":"381","author":"WJ Dewilde","year":"2013","unstructured":"Dewilde WJ, Oirbans T, Verheugt FW, Kelder JC, De Smet BJ, Herrman JP, et al. Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention: an open-label, randomised, controlled trial. Lancet. 2013;381:1107\u201315.","journal-title":"Lancet"},{"key":"1145_CR35","doi-asserted-by":"publisher","first-page":"2423","DOI":"10.1056\/NEJMoa1611594","volume":"375","author":"CM Gibson","year":"2016","unstructured":"Gibson CM, Mehran R, Bode C, Halperin J, Verheugt FW, Wildgoose P, et al. Prevention of bleeding in patients with atrial fibrillation undergoing PCI. N Engl J Med. 2016;375:2423\u201334.","journal-title":"N Engl J Med"},{"key":"1145_CR36","doi-asserted-by":"publisher","first-page":"1513","DOI":"10.1056\/NEJMoa1708454","volume":"377","author":"CP Cannon","year":"2017","unstructured":"Cannon CP, Bhatt DL, Oldgren J, Lip GYH, Ellis SG, Kimura T, et al. Dual antithrombotic therapy with dabigatran after PCI in atrial fibrillation. N Engl J Med. 2017;377:1513\u201324.","journal-title":"N Engl J Med"},{"key":"1145_CR37","first-page":"1455","volume":"38","author":"S Halvorsen","year":"2017","unstructured":"Halvorsen S, Storey RF, Rocca B, Sibbing D, Ten Berg J, Grove EL, et al. Management of antithrombotic therapy after bleeding in patients with coronary artery disease and\/or atrial fibrillation: expert consensus paper of the European Society of Cardiology Working Group on thrombosis. Eur Heart J. 2017;38:1455\u201362.","journal-title":"Eur Heart J"},{"key":"1145_CR38","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1681\/ASN.2011070658","volume":"23","author":"JY Yang","year":"2012","unstructured":"Yang JY, Lee TC, Montez-Rath ME, Paik J, Chertow GM, Desai M, et al. Trends in acute nonvariceal upper gastrointestinal bleeding in dialysis patients. J Am Soc Nephrol. 2012;23:495\u2013506.","journal-title":"J Am Soc Nephrol"},{"key":"1145_CR39","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1161\/01.CIR.76.1.142","volume":"76","author":"JH Chesebro","year":"1987","unstructured":"Chesebro JH, Knatterud G, Roberts R, Borer J, Cohen LS, Dalen J, et al. Thrombolysis in myocardial infarction (TIMI) trial, phase I: a comparison between intravenous tissue plasminogen activator and intravenous streptokinase. Clinical findings through hospital discharge. Circulation. 1987;76:142\u201354.","journal-title":"Circulation"},{"key":"1145_CR40","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1056\/NEJM199309023291001","volume":"329","author":"GUSTO Investigators","year":"1993","unstructured":"GUSTO Investigators. An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. N Engl J Med. 1993;329:673\u201382.","journal-title":"N Engl J Med"},{"key":"1145_CR41","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1093\/eurheartj\/ehv381","volume":"37","author":"EC Hansson","year":"2016","unstructured":"Hansson EC, Jideus L, Aberg B, Bjursten H, Dreifaldt M, Holmgren A, et al. Coronary artery bypass grafting-related bleeding complications in patients treated with ticagrelor or clopidogrel: a nationwide study. Eur Heart J. 2016;37:189\u201397.","journal-title":"Eur Heart J"},{"key":"1145_CR42","doi-asserted-by":"publisher","first-page":"1346","DOI":"10.1093\/ndt\/gft033","volume":"28","author":"F Locatelli","year":"2013","unstructured":"Locatelli F, Barany P, Covic A, De Francisco A, Del Vecchio L, Goldsmith D, et al. Kidney disease: improving global outcomes guidelines on anaemia management in chronic kidney disease: a European renal best practice position statement. Nephrol Dial Transplant. 2013;28:1346\u201359.","journal-title":"Nephrol Dial Transplant"},{"key":"1145_CR43","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1111\/j.1525-139X.2006.00179.x","volume":"19","author":"D Kaw","year":"2006","unstructured":"Kaw D, Malhotra D. Platelet dysfunction and end-stage renal disease. Semin Dial. 2006;19:317\u201322.","journal-title":"Semin Dial"},{"key":"1145_CR44","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.blre.2014.03.001","volume":"28","author":"PJ Svensson","year":"2014","unstructured":"Svensson PJ, Bergqvist PB, Juul KV, Berntorp E. Desmopressin in treatment of haematological disorders and in prevention of surgical bleeding. Blood Rev. 2014;28:95\u2013102.","journal-title":"Blood Rev"},{"key":"1145_CR45","doi-asserted-by":"publisher","first-page":"1706","DOI":"10.1056\/NEJMoa060989","volume":"354","author":"DL Bhatt","year":"2006","unstructured":"Bhatt DL, Fox KA, Hacke W, Berger PB, Black HR, Boden WE, et al. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med. 2006;354:1706\u201317.","journal-title":"N Engl J Med"},{"key":"1145_CR46","doi-asserted-by":"publisher","first-page":"2001","DOI":"10.1056\/NEJMoa0706482","volume":"357","author":"SD Wiviott","year":"2007","unstructured":"Wiviott SD, Braunwald E, McCabe CH, Montalescot G, Ruzyllo W, Gottlieb S, et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2007;357:2001\u201315.","journal-title":"N Engl J Med"},{"key":"1145_CR47","doi-asserted-by":"publisher","first-page":"1297","DOI":"10.1056\/NEJMoa1205512","volume":"367","author":"MT Roe","year":"2012","unstructured":"Roe MT, Armstrong PW, Fox KA, White HD, Prabhakaran D, Goodman SG, et al. Prasugrel versus clopidogrel for acute coronary syndromes without revascularization. N Engl J Med. 2012;367:1297\u2013309.","journal-title":"N Engl J Med"},{"key":"1145_CR48","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1056\/NEJMoa0904327","volume":"361","author":"L Wallentin","year":"2009","unstructured":"Wallentin L, Becker RC, Budaj A, Cannon CP, Emanuelsson H, Held C, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2009;361:1045\u201357.","journal-title":"N Engl J Med"},{"key":"1145_CR49","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1056\/NEJMoa010746","volume":"345","author":"S Yusuf","year":"2001","unstructured":"Yusuf S, Zhao F, Mehta SR, Chrolavicius S, Tognoni G, Fox KK. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med. 2001;345:494\u2013502.","journal-title":"N Engl J Med"},{"key":"1145_CR50","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.1093\/eurheartj\/ehv531","volume":"37","author":"MP Bonaca","year":"2016","unstructured":"Bonaca MP, Bhatt DL, Steg PG, Storey RF, Cohen M, Im K, et al. Ischaemic risk and efficacy of ticagrelor in relation to time from P2Y12 inhibitor withdrawal in patients with prior myocardial infarction: insights from PEGASUS-TIMI 54. Eur Heart J. 2016;37:1133\u201342.","journal-title":"Eur Heart J"},{"key":"1145_CR51","doi-asserted-by":"publisher","first-page":"2155","DOI":"10.1056\/NEJMoa1409312","volume":"371","author":"L Mauri","year":"2014","unstructured":"Mauri L, Kereiakes DJ, Yeh RW, Driscoll-Shempp P, Cutlip DE, Steg PG, et al. Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents. N Engl J Med. 2014;371:2155\u201366.","journal-title":"N Engl J Med"},{"key":"1145_CR52","doi-asserted-by":"publisher","first-page":"2371","DOI":"10.1016\/S0140-6736(15)60263-X","volume":"385","author":"T Palmerini","year":"2015","unstructured":"Palmerini T, Benedetto U, Bacchi-Reggiani L, Della Riva D, Biondi-Zoccai G, Feres F, et al. Mortality in patients treated with extended duration dual antiplatelet therapy after drug-eluting stent implantation: a pairwise and Bayesian network meta-analysis of randomised trials. Lancet. 2015;385:2371\u201382.","journal-title":"Lancet"},{"key":"1145_CR53","doi-asserted-by":"publisher","first-page":"h1618","DOI":"10.1136\/bmj.h1618","volume":"350","author":"EP Navarese","year":"2015","unstructured":"Navarese EP, Andreotti F, Schulze V, Kolodziejczak M, Buffon A, Brouwer M, et al. Optimal duration of dual antiplatelet therapy after percutaneous coronary intervention with drug eluting stents: meta-analysis of randomised controlled trials. BMJ. 2015;350:h1618.","journal-title":"BMJ"},{"key":"1145_CR54","doi-asserted-by":"publisher","first-page":"1298","DOI":"10.1016\/j.jacc.2015.01.039","volume":"65","author":"G Giustino","year":"2015","unstructured":"Giustino G, Baber U, Sartori S, Mehran R, Mastoris I, Kini AS, et al. Duration of dual antiplatelet therapy after drug-eluting stent implantation: a systematic review and meta-analysis of randomized controlled trials. J Am Coll Cardiol. 2015;65:1298\u2013310.","journal-title":"J Am Coll Cardiol"},{"key":"1145_CR55","doi-asserted-by":"publisher","first-page":"1340","DOI":"10.1016\/j.jacc.2012.06.043","volume":"60","author":"BK Kim","year":"2012","unstructured":"Kim BK, Hong MK, Shin DH, Nam CM, Kim JS, Ko YG, et al. A new strategy for discontinuation of dual antiplatelet therapy: the RESET trial (REal safety and efficacy of 3-month dual antiplatelet therapy following endeavor zotarolimus-eluting stent implantation). J Am Coll Cardiol. 2012;60:1340\u20138.","journal-title":"J Am Coll Cardiol"},{"key":"1145_CR56","first-page":"2510","volume":"310","author":"F Feres","year":"2013","unstructured":"Feres F, Costa RA, Abizaid A, Leon MB, Marin-Neto JA, Botelho RV, et al. Three vs twelve months of dual antiplatelet therapy after zotarolimus-eluting stents: the OPTIMIZE randomized trial. JAMA. 2013;310:2510\u201322.","journal-title":"JAMA"},{"key":"1145_CR57","doi-asserted-by":"publisher","first-page":"2038","DOI":"10.1056\/NEJMoa1503943","volume":"373","author":"P Urban","year":"2015","unstructured":"Urban P, Meredith IT, Abizaid A, Pocock SJ, Carrie D, Naber C, et al. Polymer-free drug-coated coronary stents in patients at high bleeding risk. N Engl J Med. 2015;373:2038\u201347.","journal-title":"N Engl J Med"},{"key":"1145_CR58","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1016\/j.jacc.2014.11.053","volume":"65","author":"M Valgimigli","year":"2015","unstructured":"Valgimigli M, Patialiakas A, Thury A, McFadden E, Colangelo S, Campo G, et al. Zotarolimus-eluting versus bare-metal stents in uncertain drug-eluting stent candidates. J Am Coll Cardiol. 2015;65:805\u201315.","journal-title":"J Am Coll Cardiol"},{"key":"1145_CR59","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1016\/j.jcin.2015.10.001","volume":"9","author":"JB Hermiller","year":"2016","unstructured":"Hermiller JB, Krucoff MW, Kereiakes DJ, Windecker S, Steg PG, Yeh RW, et al. Benefits and risks of extended dual antiplatelet therapy after everolimus-eluting stents. JACC Cardiovasc Interv. 2016;9:138\u201347.","journal-title":"JACC Cardiovasc Interv"},{"key":"1145_CR60","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1016\/j.ijcard.2015.08.058","volume":"201","author":"F Costa","year":"2015","unstructured":"Costa F, Adamo M, Ariotti S, Navarese EP, Biondi-Zoccai G, Valgimigli M. Impact of greater than 12-month dual antiplatelet therapy duration on mortality: drug-specific or a class-effect? A meta-analysis. Int J Cardiol. 2015;201:179\u201381.","journal-title":"Int J Cardiol"},{"issue":"12","key":"1145_CR61","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.115.002524","volume":"4","author":"F Costa","year":"2015","unstructured":"Costa F, Tijssen JG, Ariotti S, Giatti S, Moscarella E, Guastaroba P, et al. Incremental value of the CRUSADE, ACUITY, and HAS-BLED risk scores for the prediction of hemorrhagic events after coronary stent implantation in patients undergoing long or short duration of dual antiplatelet therapy. J Am Heart Assoc. 2015;4(12):e002524.","journal-title":"J Am Heart Assoc"},{"key":"1145_CR62","first-page":"1034","volume":"38","author":"T Palmerini","year":"2017","unstructured":"Palmerini T, Della Riva D, Benedetto U, Bacchi Reggiani L, Feres F, Abizaid A, et al. Three, six, or twelve months of dual antiplatelet therapy after DES implantation in patients with or without acute coronary syndromes: an individual patient data pairwise and network meta-analysis of six randomized trials and 11 473 patients. Eur Heart J. 2017;38:1034\u201343.","journal-title":"Eur Heart J"},{"key":"1145_CR63","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1016\/S0140-6736(15)00979-4","volume":"387","author":"S Cassese","year":"2016","unstructured":"Cassese S, Byrne RA, Ndrepepa G, Kufner S, Wiebe J, Repp J, et al. Everolimus-eluting bioresorbable vascular scaffolds versus everolimus-eluting metallic stents: a meta-analysis of randomised controlled trials. Lancet. 2016;387:537\u201344.","journal-title":"Lancet"},{"key":"1145_CR64","doi-asserted-by":"publisher","first-page":"2479","DOI":"10.1016\/S0140-6736(16)32050-5","volume":"388","author":"PW Serruys","year":"2016","unstructured":"Serruys PW, Chevalier B, Sotomi Y, Cequier A, Carrie D, Piek JJ, et al. Comparison of an everolimus-eluting bioresorbable scaffold with an everolimus-eluting metallic stent for the treatment of coronary artery stenosis (ABSORB II): a 3 year, randomised, controlled, single-blind, multicentre clinical trial. Lancet. 2016;388:2479\u201391.","journal-title":"Lancet"},{"key":"1145_CR65","doi-asserted-by":"publisher","first-page":"1901","DOI":"10.1016\/j.jacc.2015.08.853","volume":"66","author":"L Raber","year":"2015","unstructured":"Raber L, Brugaletta S, Yamaji K, O\u2019Sullivan CJ, Otsuki S, Koppara T, et al. Very late scaffold thrombosis: intracoronary imaging and histopathological and spectroscopic findings. J Am Coll Cardiol. 2015;66:1901\u201314.","journal-title":"J Am Coll Cardiol"},{"key":"1145_CR66","doi-asserted-by":"publisher","first-page":"2736","DOI":"10.1161\/CIRCULATIONAHA.110.009449","volume":"123","author":"R Mehran","year":"2011","unstructured":"Mehran R, Rao SV, Bhatt DL, Gibson CM, Caixeta A, Eikelboom J, et al. Standardized bleeding definitions for cardiovascular clinical trials: a consensus report from the bleeding academic research consortium. Circulation. 2011;123:2736\u201347.","journal-title":"Circulation"}],"container-title":["BMC Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12916-018-1145-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12916-018-1145-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12916-018-1145-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,9]],"date-time":"2024-07-09T15:47:51Z","timestamp":1720540071000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcmedicine.biomedcentral.com\/articles\/10.1186\/s12916-018-1145-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,9,19]]},"references-count":66,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["1145"],"URL":"https:\/\/doi.org\/10.1186\/s12916-018-1145-0","relation":{},"ISSN":["1741-7015"],"issn-type":[{"value":"1741-7015","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,9,19]]},"assertion":[{"value":"11 April 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 August 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 September 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"AC speaker and consulting fees for Vifor-Fresenius, Otsuka, and Roche. SG speaker fees for Boeringher and Shire. AO consultant for Sanofi Genzyme and Servier, and speaker fees for Amgen, Shire, and Otsuka. PR speaker and consulting fees for Astra-Zeneca, Bayer, Novartis, Relypsa, Stealth Peptides, and Vifor Fresenius Medical Care Renal Pharma, and co-founder of CardioRenal. MB speaker fees for Amgen, Abbott, Actavis, KRKA, MSD, Mylan, and Sanofi. AB speaker fees for Astra Zeneca, Sanofi, Boeringher Ingelheim, and Pfizer. None of these companies influenced this work.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"158"}}